A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (SPIRIT P3)

The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Psoriatic Arthritis
What the trial is testing?
Ixekizumab
Could I receive a Placebo?
Yes
Enrollment Goal
394
Trial Dates
Sep 14, 2015 - Oct 30, 2018
How long will I be in the trial?
Your participation could last up to 2.5 years and include 32 visits to the study center.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.